Comparative Pharmacology
Head-to-head clinical analysis: FORADIL versus LANOPHYLLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORADIL versus LANOPHYLLIN.
FORADIL vs LANOPHYLLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Formoterol is a long-acting beta2-adrenergic receptor agonist (LABA) that relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.
Lanophyllin is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation, respiratory stimulation, and anti-inflammatory effects.
Inhalation: 12 mcg twice daily (every 12 hours) via Foradil Aerolizer.
5-6 mg/kg IV loading dose over 20-30 minutes, then 0.4-0.6 mg/kg/hour continuous IV infusion; maintenance oral dose 300-600 mg/day in divided doses every 8-12 hours.
None Documented
None Documented
Terminal half-life: 7-10 hours. Steady-state achieved within 3-5 days; clinical context: allows twice-daily dosing for bronchodilation.
Terminal elimination half-life is 7-9 hours in healthy adults; increases to 20-30 hours in congestive heart failure, cirrhosis, or severe COPD; decreases to 3-5 hours in smokers (tobacco or marijuana) due to enzyme induction.
Renal (60% as unchanged drug and metabolites) and fecal (40% as metabolites).
Renal excretion of unchanged drug accounts for approximately 10% of elimination; hepatic metabolism accounts for 90%, with metabolites excreted in urine. Biliary/fecal excretion is negligible (<2%).
Category C
Category C
Bronchodilator
Bronchodilator